N
Google TrendGME (1000+) — GameStop Stock Hits a New 52-Week High: What's Going On?
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:gme1000+pope francis200+nicolò tresoldi500+michael olise1000+bank of america fine1000+club brugge500+rb leipzig200+saudi news1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Real-world outcomes of br" (30 stories)

Top Headline Story

Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities
Lead StoryNatureworld
Jun 8

Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE80TGEydUt0enlLb3ByU0RLVzV2MHZOWm9pekhqbGdVYWc0WUtSZ3hlUHB5dExya1lmY0dJMEl2b0x4QUZCWEZqY3NwbThoY1V4MTdfX05wYklYQ3VON3FN?oc=5" target="_blank">Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
1000+23m ago

gme

GameStop Stock Hits a New 52-Week High: What's Going On?

Filter stories
200+23m ago

pope francis

The Myth of St. Francis

Filter stories
500+33m ago

nicolò tresoldi

Nicolò Tresoldi, chi è l'attaccante del Bruges che spaventa l'Inter in Champions League

Filter stories
1000+33m ago

michael olise

The Ballon d’Or doesn’t capture football’s wonder – Michael Olise is proof | Zito Madu

Filter stories

Search Results for "Real-world outcomes of br"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Real-World Outcomes of Colorectal Signet Ring Cell Carcinoma: Clinicopathological Characteristics, Treatment Patterns, and Survival
The Cureus Journal of Medical Scienceworld

Real-World Outcomes of Colorectal Signet Ring Cell Carcinoma: Clinicopathological Characteristics, Treatment Patterns, and Survival

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxPc2RoWkVoR1NxbllSb0xOX1hwRjVjTGcwYjIwRDhWNkxCbUlxU0dRUkZDZUhRT204MVlSVDhEUmVqdFJTWEJ1VVhCbndLMkdIbWYwcVM5WVNoTExiS2FoRjFNU3pvaWhmdG85Smt4LTg4V3RqVlRPb1dtZ2xXaXZkbnZqUFdvNnplRHY5YTVjX2pyeUFuNlVLeXFPaTc4MGVBdXc3WXlBZm83QkRQcGpHbS1iZ0ZPOFdWZG5DOVBncjhxd2JaTFNWN0lqTDNuWTBKZ2tFaS1HTzNNelZOcmdTRHZkbGF2YUExYjBtMXFkenJwb1kwOFlrMV8wTQ?oc=5" target="_blank">Real-World Outcomes of Colorectal Signet Ring Cell Carcinoma: Clinicopathological Characteristics, Treatment Patterns, and Survival</a>  <font color="#6f6f6f">The Cureus Journal of Medical Science</font>

Read Full StoryMore like this
Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service
Natureworld

Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE01ZTVwbk5COUZoR0RETTdNNGtjRzFZOG4xU1B6ZURHWnNXQlEyX3JWSmx4ajlfbGVWTE14UC1tX3ZhZUxCbHNmYlIwNjdTOGptU0twbFNiUjNodXVHcFVz?oc=5" target="_blank">Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis
Frontiersworld

Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNNUNhRkdiWFJMcUtGbmFhQlRWUGx3Rk5XbFZoRlRIM3dzWGFjM1RDM09uSmVhcnpvNUFpUmk4dGR6am9qY2tkQkRHZ3BRQ1RENHp4SmxtZUxiRThXSjlrdTZOR1oxNm9hbkRRU2RRdU84Q3pfcDgzMUQ2dHZySkNMa0d6Ry1qenJ5SVdUVGJkemJTZw?oc=5" target="_blank">Real-world outcomes of lurasidone augmentation for treatment-resistant bipolar depression: a retrospective observational analysis</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Anthracycline-containing versus anthracycline-free carboplatin-based
Bioengineer.orgtech

Anthracycline-containing versus anthracycline-free carboplatin-based

<a href="https://news.google.com/rss/articles/CBMi-wFBVV95cUxQQWxiOUxWWGxFQmpRUldKemN3Z3kzVkdWcElqUi1JQ01NRUhVS3RzZFlYSXNNeXlVUms2OFZHcUhKQkdJdkhPd3JicDRJV3ZRY3BMYVZ3cDFNX181TEVNSURLV3NobC1odEp1cWltSmRBSnBDRDFycFRIMjdLdmVzVFFYbE1aZUVmLWVVaEFjTEc1blB3OWFLUzdNSFRIcXhfWEZnT2d5NjVCcU82TEduV0MwRkpydWtXOXZMMkc1RFBPMEplTUN4OHhraDUyYWVOb0o1eEMwd05qcVhRYmV1QlV0WkJObWJwNTE0cVFPZ3dLYlVyT0pyUnloMA?oc=5" target="_blank">Anthracycline-containing versus anthracycline-free carboplatin-based</a>  <font color="#6f6f6f">Bioengineer.org</font>

Read Full StoryMore like this
Dassault Systèmes to acquire ArisGlobal, creating a unified
GlobeNewswireworld

Dassault Systèmes to acquire ArisGlobal, creating a unified

<a href="https://news.google.com/rss/articles/CBMi4AJBVV95cUxPdHhKX05ORk5sVWlhSm5RdGUzaUdJb3cxYlJ5YmVJcXRORXVrR2hiUlJobVUwMWVyYTllMHNDZm9zQTY0NkRwczlkbXlzVXpnajFncW5pcFhGV0R1LW45SDVUdEJfM2lmTFBUTHFsT3Y4R01LUVZ5ekZ1eVlWLVkzRTNJSGFzMFZLNUVaMTNBT0RFMHBJaE12WXAwZUpIUnQyaTZPTE5fVkp5eXY3OVV0RXp1R1FtRlZOT1hTYUVYeFBmZ1hwenZ1U3c5Tk1yYVhwczI5d1JidmhWQk1OUEkwaXZZRlgwdUJGYUEwTmxIN0xfTk82ZHZ1c0YtVTFOaHkwWTBDaTVUaXJtTmNtYUZRc1NObVdKbThoMWxDcFpvUjZJSmM2YzhQbnlhUGRiQ25CWXFoQUc1Y1dXVWFVWEJ3NzlPcE44cVVUQjBFdXNxdXVJb3RiMGJKQVpObnAzaTR3?oc=5" target="_blank">Dassault Systèmes to acquire ArisGlobal, creating a unified</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study
Natureworld

Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9vSk8ydHMyU1hmNTlLaWxEUG93U3JCNEkxSGE4V1h2Z1lsU0lSdkt2bTlta1hGYVN4R3o5aTFFSGZMY1ZoYlRWUU1lTENWcDgteGk4VnNzOEIxRGtqbWd3?oc=5" target="_blank">Aflibercept biosimilar use and real-world outcomes in various retinal diseases: the AURA Korea study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma
Natureworld

Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBneGthaS0tT2VzV2xXSGV0cEFyaVRDbG5pY0ZwbGVJVzdpa3FwSXFMOEg1V1RBZGxCdWtfaVJnSVZwZE5MVnZnQXRTaHRHc19EYWN4R1dnY1MtM2cxbHFr?oc=5" target="_blank">Real world outcomes of intravitreal and systemic therapy in primary and secondary vitreoretinal lymphoma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin’s Lymphoma: A Study From a Single Tertiary Care Center
Cureusworld

Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin’s Lymphoma: A Study From a Single Tertiary Care Center

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxNQm1xam5pSEVYaUVPTGw2ck5KNmJkV2cyS2htRGV2TzZWU1JmcEROMUNpc25pZHJaanloZHdDeHBVdXR1YWEtWHJBNXBMMWtkcjRnY05hNVVQeVhCWnJkaVZpdkUyWHZ6VzFyUFo2NnRKbTFucllzbnktdVhQcGR2UzJxZGREeVJGaVZIcl9OTlVGSFdycjUtd0FyY2lZaFdnSG5lcDhYbWNPTWpjelo3bGF6c1JLellXRnNLTWxiTk9qZFoyUTl2WmVvOUpBeklud1NJZnh5UjI1aURNWXN2OWtMNnNPSENyckNocg?oc=5" target="_blank">Real-World Outcomes of PET-Adapted Treatment for Classic Hodgkin’s Lymphoma: A Study From a Single Tertiary Care Center</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Incident mental disorders following cancer: analysis of real-world psychiatric outcomes in a nationwide population-based cohort study in Denmark across three decades
Natureworld

Incident mental disorders following cancer: analysis of real-world psychiatric outcomes in a nationwide population-based cohort study in Denmark across three decades

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5FVkpEaG1wRkJWbWw2RjlYMnVDRUUzbmJjNThuU3k4Mi1hYVZyVU1VVjFLVDFwT3A0YkVEUEU1RnRYcXYzQ0xPSTh1aDN4cHNJNjQ1WWpGdzhJbW5uTjdv?oc=5" target="_blank">Incident mental disorders following cancer: analysis of real-world psychiatric outcomes in a nationwide population-based cohort study in Denmark across three decades</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial
Natureworld

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFAyZy1hMGNUbGtOeEtOUjE5cXZ5bzY1ZFFLYTRWc2U1UnNWSU51WWJNZURDbFptWENRX1d2VzVTY3IwQS1jRDU1aENRMW5UTmJqb2VMWmNldXBwRUgxYXlF?oc=5" target="_blank">Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
Natureworld

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5YUFhMaFdNcC1WSXlnTUJuZDRTTUZLUUVmSU1TWHFjRUJUUTd0Znk2RkVQQWp4aS1FOEVnd2wxUTJnWU5wZG81MGNnSzhQbEZ2YUlxVkZJY2lJeFYwTTdr?oc=5" target="_blank">Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer
Natureworld

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE8tNDVOZ0FERE44ejUwZWx0dGhSOHJTb0x4ZmZkelRBQmZ3ektjRFVqS29hZkhteG41cXl0WnE1dGVqMlU2LThyeXVyNW0tN0RWOUMxNG5CRklYOC1CejNR?oc=5" target="_blank">Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea Study
Natureworld

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea Study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5NYzQyZmxhZXA1RnBUMmFyUGV5WnVpUzBOUzZvaVl6NmdpYTRkWnpfWEdlNWd2YVNDVFh4bkpUNE1icFlnUFl4VkpDbFhXRlRsVHBsaG9kZE9Uc1p5LTA0?oc=5" target="_blank">Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience—ROSE Korea Study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience | Blood Cancer Journal
Natureworld

Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience | Blood Cancer Journal

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3WWc3Nzk1b25uaVJKUkpZSXZaaGxiVkdMVl9JRU9sWml5Z2NHMzBVamhLRHZ2VkVlWEp0SEZyUlFRYVNpZVFkYW1fYV9HdWVnb1B5T3o2T0hMTkgwLUw4?oc=5" target="_blank">Real world outcomes with elotuzumab-based therapies for patients with relapsed refractory multiple myeloma: a Mayo Clinic experience | Blood Cancer Journal</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period
Natureworld

Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5HSVBBRXRZcjhfaGZ5dkNPbnRqUXVKdkc1YVFqRER2Z2JxX0pSNVNwaXRjd1R2MXRsSVozRklKTHpUUzRMVjlDTmFKRW1DSFhGSzN2eVZEX1NnYkRoUFh3?oc=5" target="_blank">Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study | Eye
Natureworld

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study | Eye

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5ZaktpRFZleERSeWNMNUVrcE05QUg5Y1lZRWlGcUVpQWZraUMwMGFNeHhUVEdIdzVtdmczOHNUV0x0blIzcDFTamQwR05hN0JrRzVMaURBZHljRlR0blVV?oc=5" target="_blank">Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study | Eye</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations
Natureworld

Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1uSE9tY1o1X1lod3lIV3N4ZjNfRk5QV0dhT2ZXSlRtSGpGWGk0SUo0ZnpMcFVnelVrNXh1WnRlZldvQjRiZnJsY1piNVg4ZWtBREVkQ1ZhRmEzVTJMS1dz?oc=5" target="_blank">Evaluating generalizability of oncology trial results to real-world patients using machine learning-based trial emulations</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma
Natureworld

KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE16b1gweFRYMkZUZEdCMURoRkN1U0RrNUJfN2E0SjVSQzZCOHF5OXI3OXF6SS00X2FzSUZ4Zk50LTlnblVxZGFSVTFGX2tyZ2REWjF0ZHJhZElLZ1RKT28w?oc=5" target="_blank">KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases
Natureworld

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9IRkFnODVNemp3NC1peVFFVXVZbkx0Y0VIVlBhSmcweVlwVUJ3ZXdjTHhPNlNRRGgzWFdid25PUzlVYlkxdXgyenBNTFhxcXZ2aWdNRmg4VUdsNUwwSHVN?oc=5" target="_blank">Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study
Natureworld

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9PSjJ6RjF5bmJnR2RnZFNaMHRaUHpwWVdiRVdSa0FpQVltcy1SaUE3SmlibHhoWkpjSmpTNkZQV2VnS01WcmhUQnVwR1Z6WlBJLVl1Ym9MZFgyV2pmTmRR?oc=5" target="_blank">Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study
Natureworld

Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBITDh2NlJFVVd1UFhFVVhMbldLWGN2MTAwY21IclRhWGVBQXdkMHN0YklzU2dYTEhEUnlPTzNBZU5qaGNsSVJzd2dmS0M0S2h4NEJ6TWN4M19MMTVJd2Rr?oc=5" target="_blank">Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Optimal timing of cancer treatments: a call for emerging evidence from clinical trials and real-world studies
Natureworld

Optimal timing of cancer treatments: a call for emerging evidence from clinical trials and real-world studies

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE80V2hrdHNEanFnY3doUXhaRzFOb3VKaFYxQnRPWVhCTlVSemF0Vk9iVEViNVBUMWhER29TcHpjbGluNkJyNGRxSFlmdkU5MGRpMF8tOTN2b2lJbVJOYzhB?oc=5" target="_blank">Optimal timing of cancer treatments: a call for emerging evidence from clinical trials and real-world studies</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance
Frontiersworld

MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPN2RnTmhYb0t2VDk0c1dGUGZvcGxfNXpQaV9sbjNuam52el9Ra19mMUVfR29ScDVTU2hqbkJKQ3VIcFdrazBzZnJZUGVqRXAxUURDTWktVjlCZFBZZEVjTGlTSm40MGg4cXNxMXV4TkFKUlFWUzBLSm9RMnEzOVZXZnJaa0gxVHYtYnJsdFVR?oc=5" target="_blank">MRI biomarkers of primary CNS lymphoma outcome after MATRix: real world performance</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Evolution of TAVR as a Technology: Do Real-World Outcomes Still Support Expanded Use?
American Heart Association Journalstech

Evolution of TAVR as a Technology: Do Real-World Outcomes Still Support Expanded Use?

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE04MjN6amZVd2JPaWl5WWV1UFNnS25xU01ZaFpsY2dXMXZOcEVreGdFbmUtdmR4YzFlQ0ptNkx3bG5JaWgtN0ZLdlFjSDNiaEoyVTJ3aGhkV1duSnNHN3BYdUhXZWNpeGNNakxzekpBcThBVzg?oc=5" target="_blank">Evolution of TAVR as a Technology: Do Real-World Outcomes Still Support Expanded Use?</a>  <font color="#6f6f6f">American Heart Association Journals</font>

Read Full StoryMore like this
Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis
Natureworld

Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBQVy1MRE14MTRmUW9YMXVFdTVyd0FuN3MycDZHeUU3NDhvc0JPV0FXRS1VeklQdG1KTU5RSFBtd0FSS29vMG1WQnJsQnlwSzdSLVR3UDZjb3AyV1gzTlpF?oc=5" target="_blank">Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Real-world outcomes with lisocabtagene maraleucel in R/R LBCL
Lymphoma Hubworld

Real-world outcomes with lisocabtagene maraleucel in R/R LBCL

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPZWp5SHhzdE9LUmpIdFRZZGpzdU1OZmVaX1JtU0R1QmVITXhmS3NqR0hrVWkwdGVTZ2FPS3lJQ2tFTlBydDBQdWM3WUQ0aHdIM3lyYTZBM2pMbWViMWpiNVFZT1Y0OGdxVHpZbXpDeHQ3a1Z3MG9iQ0ltSzNYWTViSTFCTzYwSWZwTXAxUU8wV00xa1FlWEdMakd2RFF2aDJSSXRHU25Paw?oc=5" target="_blank">Real-world outcomes with lisocabtagene maraleucel in R/R LBCL</a>  <font color="#6f6f6f">Lymphoma Hub</font>

Read Full StoryMore like this
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Naturegeneral

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5PUGlnSU51MXhSeW1ESGlxOWcxV3lESmZmakd6dG1TazFwV01HdFlBZVczYXdhTU5jUlpydXFwYmlxbnJuQVdjSkRwc0R1enRMQUxoSEVGV252M2xZdGZJ?oc=5" target="_blank">Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL
OncLivetech

Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOWnJNeGtXbEdXU2NlcnlGNE9LSUdORXBqZGwwU1BMZnlOQjNQTkg2MlZfaXAxRkdjcHhka3dyNmFGRHk5RGwxV2o0VWxjWWNZbXcwX1h1MXRiNnVJUjFjRkZ2NU5Bdno5bnY2czV0RXpscUh4TUFtanVqRl9IWXl1NVF1VzRWZjZXNnkxMElSczNnckppc0Nr?oc=5" target="_blank">Maintenance Rituximab Prolongs Time to Next Treatment, OS in MCL</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration | Eye
Natureworld

1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration | Eye

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE10Tnd3UnNoSWs0T21HckhEOVV4VnFuQk56blJxLXg5UTQydHZDakloMnRudUxja0RDOEJSOGZxZ19fa0k5c005Y0VRQ0VDX3Z0MWc2Y3lUYVNFOUFPMWtJ?oc=5" target="_blank">1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration | Eye</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
"Real-world outcomes of br" — Live Google News Trends & Headlines